Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SG7B
|
|||
| Former ID |
DIB015232
|
|||
| Drug Name |
GLPG-0634
|
|||
| Synonyms |
Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
| Cutaneous lupus erythematosus [ICD-11: EB5Z; ICD-10: L80-L99, L93; ICD-9: 710] | Phase 2 | [2] | ||
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [3], [4] | ||
| Company |
Abbvie; galapagos
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23N5O3S
|
|||
| Canonical SMILES |
C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
|
|||
| InChI |
1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)
|
|||
| InChIKey |
RIJLVEAXPNLDTC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1206161-97-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7913). | |||
| REF 4 | ClinicalTrials.gov (NCT02048618) Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease. U.S. National Institutes of Health. | |||
| REF 5 | Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. | |||
| REF 6 | Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013 Oct 1;191(7):3568-77. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.